Aclaris Therapeutics Inc (ACRS)

Jun 09, 2026

Aclaris Therapeutics (ACRS) Gains Analyst Attention as Stifel Flags Penny Stock OpportunityEarnings Revision Report - newsline.com

Jun 09, 2026

Jun 08, 2026

Aclaris (ACRS) director Andrew Schiff reports RSU vesting and new stock option grant - Stock Titan

Jun 08, 2026

Jun 08, 2026

Aclaris Therapeutics (ACRS) director gains new RSUs and stock options - Stock Titan

Jun 08, 2026

Jun 07, 2026

Stifel Raises Aclaris Therapeutics Price Target to Four Dollars - HarianBasis.co

Jun 07, 2026

Jun 07, 2026

Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On - Insider Monkey

Jun 07, 2026

Jun 06, 2026

Aclaris Therapeutics maps busy pipeline calendar, plans phase 2 asthma trial for ATI-052 - MSN

Jun 06, 2026

Jun 04, 2026

Aclaris Stockholders Approve Directors, Pay and Auditor - TipRanks

Jun 04, 2026

Jun 04, 2026

Shareholders at Aclaris (NASDAQ: ACRS) back directors, executive pay and PwC - Stock Titan

Jun 04, 2026

Jun 04, 2026

Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052 - Yahoo Finance

Jun 04, 2026

Jun 04, 2026

ACRS: All proposals passed, with no stockholder questions submitted during the meeting - TradingView

Jun 04, 2026

Jun 04, 2026

Q2 Earnings Forecast for ACRS Issued By Lifesci Capital - MarketBeat

Jun 04, 2026

Jun 03, 2026

This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday - Benzinga

Jun 03, 2026

Jun 03, 2026

Aclaris Therapeutics Price Target Announced at $13.00/Share by LifeSci Capital - Moomoo

Jun 03, 2026

Jun 02, 2026

ACRS Initiated Coverage by LifeSci Capital -- Rating 'Outperform' - GuruFocus

Jun 02, 2026

Jun 01, 2026

Aclaris Dips Ahead of Jefferies, With Focus on 2026 Trial Data - Bez Kabli

Jun 01, 2026

May 28, 2026

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Investing News Network

May 28, 2026

May 27, 2026

Aclaris Therapeutics (ACRS) Edges Higher, Testing Key Resistance Near $4.81High Conviction Picks - The Legal Advocate

May 27, 2026

May 27, 2026

Aclaris Therapeutics (ACRS) Edges Higher, Testing Resistance After Modest UptickGrowth ETF - The Legal Advocate

May 27, 2026

May 26, 2026

Aclaris Therapeutics Holds Steady Near Mid-Range as Traders Eye Key Support and ResistanceVolume Climax - thelegaladvocate.com

May 26, 2026

May 26, 2026

Aclaris Therapeutics (ACRS) Edges Lower Amid Tight Trading RangeHigh Conviction Picks - The Legal Advocate

May 26, 2026

May 25, 2026

Aclaris Therapeutics (ACRS) Holds Near Support as Volume Suggests Cautious SentimentCTA Positioning - The Legal Advocate

May 25, 2026

May 23, 2026

Aclaris Therapeutics, Inc. Stock 12‑Month Price Target Raised to $10.2, Implies 126% Upside - TradingView

May 23, 2026

May 22, 2026

926-share sale notice for Aclaris Therapeutics (NASDAQ: ACLS) via Form 144 - Stock Titan

May 22, 2026

May 18, 2026

Aclaris Therapeutics (ACRS) price target increased by 12.65% to 9.64 - MSN

May 18, 2026

May 18, 2026

Aclaris Therapeutics, Inc.Common Stock (NQ: ACRS - The Chronicle-Journal

May 18, 2026

May 16, 2026

Aclaris Expands Immunology Pipeline Ahead of Key Trial Data - MyChesCo

May 16, 2026

May 14, 2026

ACRS: Multiple late-stage immunology assets advance toward key 2024 milestones, backed by robust funding - TradingView

May 14, 2026

May 14, 2026

ACRS: Multiple innovative I&I therapies advance toward key Phase 2b milestones in 2026 - TradingView

May 14, 2026

May 14, 2026

Aclaris (ACRS) Crushes Q1 2026 Estimates — EPS $-0.15 Tops ViewsSurprise Factor Analysis - newsline.com

May 14, 2026

May 12, 2026

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates - MSN

May 12, 2026

May 11, 2026

MSN Money - MSN

May 11, 2026

May 11, 2026

H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $16 - Moomoo

May 11, 2026

May 11, 2026

Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $11 - Moomoo

May 11, 2026

May 11, 2026

Guggenheim Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $12 - Moomoo

May 11, 2026

May 08, 2026

Oppenheimer Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo

May 08, 2026

May 08, 2026

Stifel raises Aclaris Therapeutics price target to $4 on pipeline By Investing.com - Investing.com Nigeria

May 08, 2026

May 08, 2026

Stifel raises Aclaris Therapeutics price target to $4 on pipeline - Investing.com

May 08, 2026

May 08, 2026

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference - The Manila Times

May 08, 2026

May 08, 2026

Aclaris: Q1 Earnings Snapshot - theheraldreview.com

May 08, 2026

May 07, 2026

Aclaris Therapeutics (NASDAQ: ACRS) deepens loss while boosting R&D - Stock Titan

May 07, 2026

May 07, 2026

Aclaris Therapeutics Releases Q1 2026 Financial Results - AlphaStreet

May 07, 2026

May 07, 2026

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Investing News Network

May 07, 2026

May 07, 2026

Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo

May 07, 2026

May 07, 2026

Aclaris Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 07, 2026

May 07, 2026

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance

May 07, 2026

May 07, 2026

Aclaris Therapeutics | 8-K: Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Moomoo

May 07, 2026

May 07, 2026

Aclaris (NASDAQ: ACRS) posts Q1 2026 loss but boosts cash runway - Stock Titan

May 07, 2026